A new publication dated November 1, 2026 appeared in the British Journal of Haematology. The article is titled "Updates in acute graft-versus-host disease: From novel pathogenic mechanisms to emerging therapeutic targets." It was indexed under PubMed ID 42968622. Selank is named in connection with this publication record. The publication is categorized as a review addressing pathogenic mechanisms and emerging therapeutic targets in acute graft-versus-host disease. No findings, outcomes, or conclusions from the publication are detailed in the available event data. Selank remains classified as an unapproved research compound. This brief reports only the existence and bibliographic details of the publication as provided. No efficacy, safety, or mechanistic claims about selank can be drawn from this listing alone. Readers interested in the broader context of this compound can consult the compound overview for additional background information.
Selank Referenced in New GVHD Review in Br J Haematology
Source: https://pubmed.ncbi.nlm.nih.gov/42968622/